Therapies already in use for treatment of KRAS-mutant cancers such as cetuximab, panitumumab, gefitinib and erlotinib present a big challenge in terms of the way cancers overcome the treatments and develop resistance [29]. The gene discussed is KRAS; the disease is cancer.